Search
BridgeBio Pharma Inc
BBIOAdd to Watchlist
81.070USD
-0.430-0.53%
Close 08-21 16:00（ET）
15.83BMarket Cap
LossP/E TTM
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-0.53%
5 Days
+1.52%
1 Month
-2.24%
6 Months
+19.38%
Year to Date
+5.99%
1 Year
+65.18%
Key Figures
80.980Open
81.610High
73.26KVolume
LossP/E TTM
149.50P/E Dynamic
--Dividend TTM
0.04%Turnover Ratio
81.500Prev. Close
80.230Low
5.93MTurnover
LossP/E Static
-6.29P/B
0.00%Div Yield TTM
-64.80%ROA
93.41552wk High
0.03Volume Ratio
-535.76MNet Profit
195.28MShares
-3.7466EPS TTM
0.99Beta
--ROE
46.81052wk Low
1.69%Amplitude
93.83%Gross Margin
15.83BMarket Cap
-0.38Reward/Risk
3.00%Risk Rate
AstraZeneca PLC Stock (AZN) Moved Down by 6.72% on Jul 9: A Full Analysis
• AstraZeneca shares fell after the Wainua drug failed a late-stage clinical trial. • The CARDIO-TTRansform trial did not meet its primary cardiovascular mortality reduction objectives. • High usage of competitor medication likely masked the drug's therapeutic efficacy in patients.
TradingKeyThu, Jul 9
Merck & Co Inc Stock (MRK) Moved Down by 3.19% on Jun 1: A Full Analysis
• Merck shares declined despite positive oncology data. • Large acquisition charges may impact investor sentiment. • Analyst ratings are mostly "Buy" with a positive price target.
TradingKeyMon, Jun 1
BridgeBio Pharma Inc's Score
0.32vs previous score
Forecast8.18
Financial Health8.25
Technical3.22
Valuation Dimensions9.36
Institutional Confidence10.00
Risk Assessment6.86
Media Coverage
Coverage Level
Very Low
Very High
Positive
Analyst Rating
BridgeBio Pharma Inc Technical Analysis
Technical Indicators
Sell
Summary
Sell
Moving Average
Neutral
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q2
Earnings / Forecast
-0.78/-0.58
Revenue / Forecast
243.68M/218.74M
BridgeBio Pharma Inc Profile
SectorPharmaceuticals
Ticker SymbolBBIO
Number of employees725
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Kohlberg Kravis Roberts & Co. L.P. | 6.77% |
| BlackRock Institutional Trust Company, N.A. | 6.16% |
| Viking Global Investors LP | 6.05% |
| Janus Henderson Investors | 5.62% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 36.99% |
| Investment Advisor/Hedge Fund | 35.07% |
| Hedge Fund | 13.21% |
| Private Equity | 8.58% |
Related Instruments
-0.60%
+1.04%
+0.44%
-0.17%
-1.24%
-0.53%
+1.03%
+0.42%
-0.36%
+0.39%
-0.08%
+0.40%
-0.35%
-1.20%
+1.73%
-0.66%
-2.76%
+0.33%
-4.30%
+1.25%Popular Instruments
53452.500
+199.100 (+0.37%)
29051.400
-243.200 (-0.83%)
7657.400
-12.900 (-0.17%)
14560.000
-201.000 (-1.36%)
65376.000
-609.000 (-0.92%)
6455.800
-1.800 (-0.03%)
84.802
-1.720 (-1.99%)
310.340
+0.990 (+0.32%)
208.480
-6.240 (-2.91%)
4651.580
+48.760 (+1.06%)
FAQs
What is the current price of BridgeBio Pharma Inc (BBIO)?
The current price of BridgeBio Pharma Inc (BBIO) is 81.50.
What is the symbol of BridgeBio Pharma Inc?
The ticker symbol of BridgeBio Pharma Inc is BBIO.
What is the 52-week high of BridgeBio Pharma Inc?
The 52-week high of BridgeBio Pharma Inc is 93.42.
What is the 52-week low of BridgeBio Pharma Inc?
The 52-week low of BridgeBio Pharma Inc is 46.81.
What is the market capitalization of BridgeBio Pharma Inc?
The market capitalization of BridgeBio Pharma Inc is 15.91B.
Is BridgeBio Pharma Inc (BBIO) currently rated as Buy, Hold, or Sell?
According to analysts, BridgeBio Pharma Inc (BBIO) has an overall rating of Buy, with a price target of 107.01.
What is the Earnings Per Share (EPS TTM) of BridgeBio Pharma Inc (BBIO)?
The Earnings Per Share (EPS TTM) of BridgeBio Pharma Inc (BBIO) is -3.75.